Souness J E, Carter C M, Diocee B K, Hassall G A, Wood L J, Turner N C
Dagenham Research Centre, Rhône-Poulenc Rorer Inc., Health Care Division, Essex, U.K.
Biochem Pharmacol. 1991 Jul 25;42(4):937-45. doi: 10.1016/0006-2952(91)90056-b.
Experiments have been performed to characterize guinea-pig peritoneal eosinophil cyclic nucleotide phosphodiesterase (PDE) activity and establish whether it is involved in regulating superoxide (.O2-) generation. Eosinophils were found to contain a predominantly membrane-bound cAMP PDE(s) (92.5 +/- 2.4% of total activity) which was resistant to solubilization with Triton X-100 (1%). This particulate PDE exhibited complex kinetics (Km = 1.3 and 31.4 microM) and was unaffected by cGMP (IC50 greater than 100 microM) or CaCl2 (2 mM) + calmodulin (10 units/mL). Little cGMP PDE activity was detected in either the soluble or particulate fractions. Inhibitors of the Ro-20-1724-inhibited (Type IV) cAMP PDE, namely Ro-20-1724 (IC50 = 0.92 +/- 0.43 microM), rolipram (IC50 = 0.20 +/- 0.04 microM) and denbufylline (IC50 = 0.20 +/- 0.01 microM), potently inhibited the particulate cAMP PDE, as did the non-selective inhibitors trequinsin (IC50 = 0.11 +/- 0.02 microM) and AH-21-132 (IC50 = 2.57 +/- 0.02 microM). Eosinophil cAMP PDE was resistant to SK&F 94120 (IC50 greater than 1000 microM), the cGMP-inhibited (Type III) cAMP PDE inhibitor, and the cGMP PDE (Type I) inhibitor, zaprinast, was only weakly active (IC50 = 35.33 +/- 10.74 microM). .O2- release from resting cells was potently inhibited by rolipram (IC50 = 0.05 +/- 0.03 microM) and denbufylline (IC50 = 0.06 +/- 0.04 microM) but surprisingly, in view of its potent cAMP PDE inhibitory activity, was only weakly decreased by trequinsin (IC50 = 8.0 +/- 2.7 microM). AH-21-132 (IC50 greater than 10 microM), SK&F 94120 (IC50 greater than 10 microM) and zaprinast (IC50 greater than 10 microM) were without effect. Rolipram and denbufylline alone exerted little effect on cAMP in intact cells but, in the presence of 10 microM isoprenaline, potently increased intracellular accumulation (EC50 = 0.45 +/- 0.16 and 0.28 +/- 0.08 microM, respectively). Trequinsin and AH-21-132 only weakly enhanced isoprenaline-stimulated cAMP accumulation. Although it induced a marked rise in cAMP only in the presence of isoprenaline, rolipram (50 microM) alone was able to increase the activity ratio of cAMP-dependent protein kinase from 0.24 to 0.84. The results suggest that Ro-20-1724-inhibited cAMP PDE plays a role in regulating eosinophil .O2- generation. The poor correlation between the PDE inhibitory actions of certain compounds and their effectiveness in elevating cAMP and inhibiting .O2- suggests the existence of a barrier impeding access to the enzyme.
已开展实验来表征豚鼠腹膜嗜酸性粒细胞环核苷酸磷酸二酯酶(PDE)活性,并确定其是否参与调节超氧阴离子(·O₂⁻)的生成。发现嗜酸性粒细胞主要含有一种膜结合型cAMP PDE(占总活性的92.5±2.4%),该酶对用1% Triton X - 100溶解具有抗性。这种颗粒状PDE表现出复杂的动力学(Km = 1.3和31.4 μM),不受cGMP(IC50大于100 μM)或CaCl₂(2 mM) + 钙调蛋白(10单位/mL)的影响。在可溶性或颗粒部分均未检测到明显的cGMP PDE活性。Ro - 20 - 1724抑制型(IV型)cAMP PDE的抑制剂,即Ro - 20 - 1724(IC50 = 0.92±0.43 μM)、咯利普兰(IC50 = 0.20±0.04 μM)和登布茶碱(IC50 = 0.20±0.01 μM),以及非选择性抑制剂曲喹辛(IC50 = 0.11±0.02 μM)和AH - 21 - 132(IC50 = 2.57±0.02 μM),均能有效抑制颗粒状cAMP PDE。嗜酸性粒细胞cAMP PDE对SK&F 94120(IC50大于1000 μM)具有抗性,SK&F 94120是cGMP抑制型(III型)cAMP PDE抑制剂,而cGMP PDE(I型)抑制剂扎普司特的活性较弱(IC50 = 35.33±10.74 μM)。静息细胞释放·O₂⁻受到咯利普兰(IC50 = 0.05±0.03 μM)和登布茶碱(IC50 = 0.06±0.04 μM)的有效抑制,但令人惊讶的是,鉴于其强大的cAMP PDE抑制活性,曲喹辛对其的抑制作用较弱(IC50 = 8.0±2.7 μM)。AH - 21 - 132(IC50大于10 μM)、SK&F 94120(IC50大于10 μM)和扎普司特(IC50大于10 μM)均无作用。咯利普兰和登布茶碱单独对完整细胞中的cAMP影响较小,但在存在10 μM异丙肾上腺素的情况下,能有效增加细胞内积累(EC50分别为0.45±0.16和0.28±0.08 μM)。曲喹辛和AH - 21 - 132仅微弱增强异丙肾上腺素刺激的cAMP积累。尽管咯利普兰(50 μM)仅在存在异丙肾上腺素时才诱导cAMP显著升高,但它 alone就能将cAMP依赖性蛋白激酶的活性比从0.24提高到0.84。结果表明,Ro - 20 - 1724抑制型cAMP PDE在调节嗜酸性粒细胞·O₂⁻生成中起作用。某些化合物的PDE抑制作用与其升高cAMP和抑制·O₂⁻有效性之间的相关性较差,这表明存在阻碍酶作用的屏障。